Application of wighteone in preparation of medicine for treating lung cancer

A therapeutic drug, the technology of White Ketone, which is applied in the field of biomedicine, can solve the problems of no drug available and resistance to Osimertinib

Inactive Publication Date: 2021-05-14
YUNNAN AGRICULTURAL UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has been found clinically that most patients will become resistant to Osimertinib due to the occurrence of mutations such as C797S and L792H after treatment, so that no drug is available

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wighteone in preparation of medicine for treating lung cancer
  • Application of wighteone in preparation of medicine for treating lung cancer
  • Application of wighteone in preparation of medicine for treating lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Effect of natural compound Wighteone on the activity of EGFR-L858R / T790M mutant lung cancer cells

[0025] Take NCI-H1975 cells in the logarithmic growth phase, and use 2×10 4 After seeding the cell seeding amount per well in 96-well plate, in 5% CO 2 , Incubate in a cell incubator at 37°C for 16 hours to ensure that the cells can be firmly attached to the bottom of the 96-well plate. Carefully suck off the complete medium on the upper layer, then slowly add 200 μL PBS to the 96-well plate with a row gun, wash the cells, and start the drug treatment after carefully sucking off the PBS. The natural compound Wighteone was configured as a 10 mM stock solution, diluted with serum-free RPMI1640 medium, and the concentration gradient was set to 0, 0.625, 1.25, 2.5, 5, 10, 20 μM. Each treatment was set in 4 replicates, and 200 μL of prepared compound dilutions were added to each well. Place the 96-well plate added with the treatment drug in an incubator at 37°C. ...

Embodiment 2

[0028] Example 2: Effect of natural compound Wighteone on the proliferation ability of EGFR-L858R / T790M mutant lung cancer cells

[0029] Take logarithmic growth of NCI-H1975 cells. After trypsinization, the cells were counted with a cell counter. The cells were mixed to ensure the minimum error between the wells, and then 6 × 10 2 The amount of cells per well was inoculated in a 6-well plate, and incubated in a 37°C incubator for 16 hours to ensure that the cells were stably attached to the bottom of the 6-well plate. The cells were treated with drugs with concentration gradients of 0, 2.5, 5 and 10 μM, and the treatment time was 24 hours. After the treatment, the cells continued to be cultured for 14 days, and the medium was replaced every other day, and the formation of cell clones and colonies was observed. After the formation of obvious cell aggregates in the 6-well plate, the cell culture medium was aspirated, and 1 mL of methanol was added to each well to fix for 10 ...

Embodiment 3

[0031] Example 3: The natural compound Wighteone inhibits the expression of EGFR signaling pathway-related proteins in EGFR-L858R / T790M mutant lung cancer cells

[0032] The logarithmically grown cells were inoculated into 60mm culture dishes with an inoculum size of 2×10 6pcs / dish. Place the culture dish in an incubator at 37°C for about 16 hours. Take out the culture dish, wash it once with preheated PBS, pretreat the cells with 20ng / ml EGF for 5 minutes, and treat the cells with the corresponding concentration of drugs (wighteone: 0, 2.5, 5, 10 μM) for 16 hours, and set up the control. After the treatment, the culture dish was taken out of the incubator, the culture medium in the culture dish was sucked away, and an appropriate amount of general-purpose protein lysate was added to make the lysate fully contact with the cells, and the culture dish was placed on an ice box for 30 minutes. After lysis, carefully scrape off the cells at the bottom of the culture dish and tran...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a natural compound wighteone in preparation of a medicine for treating lung cancer, and belongs to the technical field of biological medicine. According to the application, biological experiments prove that the wighteone can remarkably inhibit the activity of EGFR-L858R / T790M mutant lung cancer by targeting an epidermal growth factor receptor (EGFR), lead to S-phase retardation of a cell cycle, inhibit the proliferation capacity of cells and induce cell apoptosis, so that the aim of treating a patient with the lung cancer is fulfilled. A novel effective medicine for clinically treating the EGFR-L858R / T790M mutant type lung cancer is provided.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of the natural compound vitrinone in the preparation of drugs for treating lung cancer. Background technique [0002] Lung cancer is the cancer with the highest mortality rate in the world, and about 80-85% of lung cancers are non-small cell lung cancer (NSCLC), which seriously threatens people's life and health. In recent years, with the continuous development of modern medicine, targeted therapy has become an important means of clinical tumor treatment due to its selectivity to cancer cells, high efficiency, and low side effects. Epidermal growth factor (EGFR) is a member of the ErbB (HER) receptor tyrosine kinase family, which plays a key role in many normal physiological processes such as cell proliferation, differentiation, metabolism and apoptosis. However, studies have shown that about 50% of NSCLC patients have abnormal expression of EGFR,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P35/00
CPCA61K31/352A61P35/00
Inventor 盛军王晶孙培元王宣军渠亚娜王玉娜
Owner YUNNAN AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap